You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Barusiban


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Barusiban?

Barusiban is an investigational drug.

There have been 4 clinical trials for Barusiban. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.

The most common disease conditions in clinical trials are Obstetric Labor, Premature, Infertility, and Premature Birth. The leading clinical trial sponsors are Ferring Pharmaceuticals, Tel-Aviv Sourasky Medical Center, and [disabled in preview].

There are ten US patents protecting this investigational drug and one hundred and sixty-three international patents.

Recent Clinical Trials for Barusiban
TitleSponsorPhase
Tocolytic Therapy for Preterm Labor in Multiple GestationTel-Aviv Sourasky Medical CenterPhase 3
Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine ContractionsFerring PharmaceuticalsPhase 2
Effect of Oxytocin Antagonist on Reduction of Uterine ContractionsFerring PharmaceuticalsPhase 2

See all Barusiban clinical trials

Clinical Trial Summary for Barusiban

Top disease conditions for Barusiban
trials000001111111Obstetric Labor, PrematureInfertilityPremature Birth[disabled in preview]
Top clinical trial sponsors for Barusiban
trials0112233Ferring PharmaceuticalsTel-Aviv Sourasky Medical Center[disabled in preview]

See all Barusiban clinical trials

US Patents for Barusiban

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Barusiban ⤷  Subscribe Permeant delivery system and methods for use thereof NITTO DENKO CORPORATION (Tokyo, JP) ⤷  Subscribe
Barusiban ⤷  Subscribe Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof Merck Serono S.A. (Coinsins, CH) ⤷  Subscribe
Barusiban ⤷  Subscribe 1H-pyrazoles useful in therapy Pfizer Inc (New York, NY) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 3 of 3 entries

International Patents for Barusiban

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Barusiban Australia AU2009231739 2028-03-31 ⤷  Subscribe
Barusiban Canada CA2720067 2028-03-31 ⤷  Subscribe
Barusiban Canada CA3084317 2028-03-31 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 3 of 3 entries

Barusiban: A Promising Oxytocin Antagonist for Preterm Labor and Beyond

Introduction

Barusiban, a novel oxytocin receptor antagonist, has been gaining significant attention in the medical community for its potential in managing preterm labor and other reproductive health issues. Here, we delve into the development updates, clinical trials, and market projections for this promising drug candidate.

Background on Preterm Labor

Preterm labor (PTL) affects up to 20% of all pregnancies and is a leading cause of preterm delivery, neonatal morbidity, and mortality. Current therapeutic options, known as tocolytics, are often limited by side effects and efficacy issues, highlighting the need for more effective treatments[2][5].

Mechanism of Action

Barusiban works by selectively binding to the oxytocin receptor (OTR), thereby inhibiting oxytocin-induced uterine contractions. It displays a higher affinity and selectivity for the OTR compared to other antagonists like atosiban, which contributes to its greater potency and longer duration of action[1][2][5].

Clinical Trials and Efficacy

Clinical trials conducted on cynomolgus monkeys have shown that barusiban is three to four times more potent than atosiban. It achieves a rapid onset of action within 0.5-1.5 hours and maintains its inhibitory effects on uterine contractions for over 13-15 hours, significantly longer than atosiban's 1-3 hours. The effects of barusiban are also reversible with high-dose oxytocin infusion[1][2].

In human studies, while a Phase II clinical trial did not demonstrate a statistically significant effect over the placebo group, there was a tendency towards a higher proportion of women who did not deliver within 48 hours with increasing predosing cervical length. This suggests potential benefits, although further trials are needed to confirm these findings[5].

Placental Transfer and Safety

Studies on placental transfer in rabbits, cynomolgus monkeys, and an ex vivo human cotyledon model indicate that barusiban has a low transfer rate to the fetus, ranging from 5% to 11% of the maternal level. This low transfer rate minimizes the risk of adverse fetal effects, making barusiban a safer option for pregnant women[5].

Advanced Clinical Trials and Development

Barusiban is currently in advanced clinical trials, not only for its use in preterm labor but also for its potential in aiding implantation support in Assisted Reproductive Technology (ART). Ferring, the company behind barusiban, is utilizing its recombinant DNA technology platform to further develop this peptide-based medicine[4].

Market Projection

Given its improved potency, long duration of action, and reversibility, barusiban is poised to become a significant player in the market for preterm labor treatments. The current unmet need for safe and effective tocolytics, combined with the drug's promising clinical trial results, suggests a strong market potential.

Competitive Landscape

The market for preterm labor treatments is currently dominated by drugs like atosiban, which have limitations in terms of potency and duration of action. Barusiban's superior profile could disrupt this market, offering healthcare providers and patients a more effective and safer alternative.

Regulatory Pathway

While barusiban has not yet received regulatory approval, the ongoing clinical trials and positive data from preclinical and early clinical studies position it well for future submissions to regulatory bodies such as the FDA and EMA.

Future Indications and Collaborations

Beyond preterm labor, barusiban is being explored for its potential in ART to support implantation. This dual focus could expand its market reach and make it a versatile tool in reproductive medicine. Collaborations with other pharmaceutical companies, such as the partnership between Ferring and other entities, will be crucial in maximizing its commercial potential[4].

Conclusion

Barusiban represents a significant advancement in the treatment of preterm labor and potentially other reproductive health issues. Its superior potency, longer duration of action, and low placental transfer make it an attractive candidate for addressing the unmet needs in this clinical area. As it progresses through advanced clinical trials and towards regulatory approval, barusiban is likely to become a key player in the market for tocolytics and reproductive health treatments.

Key Takeaways

  • Higher Potency and Duration: Barusiban is three to four times more potent than atosiban with a longer duration of action.
  • Low Placental Transfer: Minimal transfer to the fetus reduces the risk of adverse fetal effects.
  • Advanced Clinical Trials: Ongoing trials for preterm labor and ART support.
  • Market Potential: Strong potential to disrupt the current market for preterm labor treatments.
  • Regulatory Pathway: Positive data positions it well for future regulatory submissions.

FAQs

What is barusiban and how does it work?

Barusiban is an oxytocin receptor antagonist that inhibits oxytocin-induced uterine contractions, making it a potential treatment for preterm labor. It works by selectively binding to the oxytocin receptor.

How does barusiban compare to atosiban?

Barusiban is three to four times more potent than atosiban and has a longer duration of action (>13-15 hours compared to 1-3 hours for atosiban).

What are the safety concerns with barusiban?

Studies indicate that barusiban has a low placental transfer rate, minimizing the risk of adverse fetal effects.

Is barusiban approved for use?

No, barusiban has not yet received regulatory approval but is in advanced clinical trials.

What other potential uses does barusiban have?

Besides preterm labor, barusiban is being explored for its potential in aiding implantation support in Assisted Reproductive Technology (ART).

Sources

  1. Torsten M. Reinheimer et al., "Barusiban, A New Highly Potent and Long-Acting Oxytocin Antagonist: Pharmacokinetic and Pharmacodynamic Comparison with Atosiban in a Cynomolgus Monkey Model of Preterm Labor," The Journal of Clinical Endocrinology & Metabolism, Volume 90, Issue 4, 1 April 2005.
  2. PubMed, "Barusiban, a new highly potent and long-acting oxytocin antagonist."
  3. ObsEva Annual Report 2019, "Annual Report 2019."
  4. Ferring Global, "Reproductive medicine and maternal health."
  5. Oxford Academic, "Barusiban, a selective oxytocin receptor antagonist."

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.